DE VOS PHARMA
The computed 12-month bankruptcy probability of DE VOS PHARMA is 0.6% (low). The 2024 annual accounts show equity of €774k and a net result of €50k. Equity is growing by ~4.9% per year across the filed fiscal years. Its solvency ranks better than 70% of 1220 sector peers (fiscal year 2024). The company has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €774k |
| Net result | €50k |
| Better than sector | 70% |
| Active | 17 yrs |
Mixed profile: strong on stability, weaker on profitability.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 40.5% | 20.4% | |
| Net result | €50k | €26k | |
| Equity | €774k | €143k | |
| Gross operating margin | €135k | €217k | |
| Total assets | €1.91M | €765k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | €132k |
| Net profit | €50k |
| Cash flow | €54k |
| Staff costs | - |
| Income taxes | €20k |
| Dividends | - |
| Total assets | €1.91M |
| Equity | €774k |
| Debt | €1.14M |
| of which ≤ 1y | €572k |
| of which > 1y | €564k |
| Working capital | €-533k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 0.07 |
| Quick ratio | 0.07 |
| Working capital ratio | -27.9% |
| Solvency | 40.5% |
| Debt / equity | 1.47 |
| Long-term debt ratio | 0.73 |
| Interest coverage | 1.95 |
| Gross margin | - |
| Net margin | - |
| ROA | 2.6% |
| ROE | 6.5% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.91M |
| Fixed assets | 21/28 | €1.87M |
| Tangible fixed assets | 22/27 | €12k |
| Financial fixed assets | 28 | €1.86M |
| Current assets | 29/58 | €39k |
| Amounts receivable within one year | 40/41 | €15k |
| Investments | 50/53 | €9k |
| Cash & bank | 54/58 | €12k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.91M |
| Equity | 10/15 | €774k |
| Contributions / capital | 10/11 | €6k |
| Reserves | 13 | €767k |
| Amounts payable | 17/49 | €1.14M |
| Amounts payable after one year | 17 | €564k |
| Amounts payable within one year | 42/48 | €572k |
| Trade debts payable within one year | 44 | €1k |
| Income statement | ||
| Gross operating margin | 9900 | €135k |
| Operating result | 9901 | €128k |
| Financial income | 75 | €10k |
| Financial charges | 65 | €68k |
| Result before taxes | 9903 | €70k |
| Income taxes | 67/77 | €20k |
| Net result for the period | 9904 | €50k |
| Result to be appropriated | 9905 | €50k |
| NACE primary | Retail trade(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 16-01-2009 |
| Status | Active |
| Postal code | 2491 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 13030B0855/00M000 | Flanders | 2,135 m² | 1 · 359 m² | 9.0 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
30-10-2023 All shares are now held by a single shareholder
Technical details
{
"events": [
{
"kind": "eenhoofdigheid_declaration",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Herbert HOUBEN",
"firm_city": null,
"firm_name": null,
"office_city": "Genk",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-10-30",
"filing_date": "2023-10-26",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2023-10-25",
"unanimous": null,
"under_authorized_capital": true,
"underlying_resolution_date": "2023-10-25"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0809.148.066",
"name_full": "DE VOS PHARMA",
"legal_form": "BV",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Accountantskantoor REYNDERS \u0026 CO CV",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"geco\u00F6rdineerde statuten"
],
"shareholders_after": [
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "DE VOS Ilse",
"role": "gecommanditeerde",
"n_shares": null,
"share_class": null
},
{
"kbo": "0831.605.249",
"pct": null,
"kind": "org",
"name": "DGI CONSULTING",
"role": "commanditaire",
"n_shares": null,
"share_class": null
}
],
"share_classes_after": [
{
"n_shares": 186,
"class_name": "Gewone Aandelen",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | DE VOS PHARMA |